SCHEMBL1102829

SCHEMBL1102829

Cc1ccc(-c2c3ccccc3c(-c3ccc(C)cc3)c3ncccc23)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
COMT P21964 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.47
NPC1 O15118 1/20 0.47
HSP90AA1 P07900 1/20 0.47
TACR1 P25103 4/20 0.43
PDE9A O76083 1/20 0.43
ACHE P22303 1/20 0.42
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
HTT P42858 2/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
KCNH2 Q12809 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CKS1B P61024 1/20 0.40
SKP2 Q13309 1/20 0.40
ENPP1 P22413 1/20 0.40
CCR1 P32246 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103024 0.97 COMT (0.49) COMTL3MBTL1NPC1HSP90AA1TACR1
SCHEMBL1103159 0.88 ALDH1A1 (0.44) COMTL3MBTL1NPC1HSP90AA1TACR1
SCHEMBL1102841 0.88 L3MBTL1 (0.46) COMTL3MBTL1NPC1HSP90AA1TACR1
SCHEMBL1103109 0.87 L3MBTL1 (0.42) L3MBTL1NPC1HSP90AA1ACHETDP1
SCHEMBL1103120 0.87 L3MBTL1 (0.42) L3MBTL1NPC1HSP90AA1ACHETDP1
SCHEMBL1103081 0.87 L3MBTL1 (0.42) L3MBTL1NPC1HSP90AA1ACHETDP1
SCHEMBL1103115 0.87 L3MBTL1 (0.42) L3MBTL1NPC1HSP90AA1ACHETDP1
SCHEMBL1103030 0.87 NPC1 (0.42) COMTL3MBTL1NPC1HSP90AA1TACR1
SCHEMBL1102949 0.85 L3MBTL1 (0.41) L3MBTL1NPC1HSP90AA1ACHETDP1
SCHEMBL1102789 0.85 L3MBTL1 (0.41) L3MBTL1NPC1HSP90AA1ACHETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 COMT 435/4885L3MBTL1 1629/4885NPC1 1582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.